About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Phathom Pharmaceuticals

< Previous 1 2 Next >
News headline image
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT SAGE
News headline image
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers CDTX PHAT
News headline image
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Leadership Succession
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.